NCT07234162 is a Phase 3 clinical trial of Golidocitinib in Peripheral T-cell Lymphoma, sponsored by Dizal Pharmaceuticals.

Who is sponsoring NCT07234162?

NCT07234162 is sponsored by Dizal Pharmaceuticals.

What drugs are being tested in NCT07234162?

Interventions in NCT07234162: Golidocitinib, Chidamide, Pralatrexate, Gemcitabine, Belinostat.

What condition does NCT07234162 study?

NCT07234162 studies Peripheral T-cell Lymphoma.

Is NCT07234162 still recruiting?

NCT07234162 is currently recruiting now. Last updated 18 November 2025.

Last reviewed 2025-11-18 · How we verify

NCT07234162

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Recruiting now Phase 3 Last updated 18 November 2025

What this trial tests

Phase 3 trial testing Golidocitinib in Peripheral T-cell Lymphoma in 218 participants. Currently enrolling.

Timeline

13 May 2024

Primary endpoint
30 November 2027

31 October 2028

Quick facts

Lead sponsor	Dizal Pharmaceuticals
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	218
Start date	13 May 2024
Primary completion	30 November 2027
Estimated completion	31 October 2028
Sites	50 locations across China, Taiwan, Thailand

Drugs / interventions tested

Golidocitinib
Chidamide — full drug profile →
Pralatrexate
Gemcitabine (gemcitabine) — full drug profile →
Belinostat (belinostat) — full drug profile →

Conditions studied

Peripheral T-cell Lymphoma — all drugs for Peripheral T-cell Lymphoma →

Sponsor

Dizal Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Peripheral T-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL). This study will treat patients with pathologically confirmed PTCL who have relapsed after or been refractory/intolerant to at least one prior systemic treatment regimen(s).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

JAK Inhibitors in the Treatment of T-Cell Lymphomas: Current Evidence and Future Directions
· 2026

Verify or expand the search:

Other trials of Golidocitinib

Trials testing the same drug.

NCT07339527 — EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell L · Phase 1, PHASE2 · not yet recruiting
NCT07196163 — An Exploratory Study of Golidocitinib in Adult Patients With ITP · Phase 1, PHASE2 · not yet recruiting
NCT07093710 — Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory · Phase 1, PHASE2 · recruiting
NCT07339345 — Prospective Single-Arm Clinical Trial of GO Regimen for HLH. · Phase 2, PHASE3 · recruiting
NCT06630091 — A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of New · Phase 2 · recruiting

Other recruiting trials for Peripheral T-cell Lymphoma

Currently open trials in the same condition.

NCT07523555 — Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies · Phase 1, PHASE2 · recruiting
NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
NCT06914037 — A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies · Phase 1 · recruiting
NCT07072221 — Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients · NA · recruiting
NCT06739265 — Golidocitinib Plus CHOP in Newly Diagnosed PTCL · Phase 1, PHASE2 · recruiting

Other Dizal Pharmaceuticals trials

Trials by the same sponsor.

NCT06813365 — Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2) · Phase 1 · recruiting
NCT06084104 — DZD9008 PK Study in Hepatic Impairment Subjects · Phase 1 · completed
NCT05926180 — Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and · Phase 1 · completed
NCT05824585 — DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · Phase 1 · recruiting
NCT06276283 — DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07234162 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dizal Pharmaceuticals
Last refreshed: 18 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07234162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing